Optimized early care for head and neck squamous cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

After surgery, many patients struggle to start and complete cisplatin‑based postoperative chemoradiation because of recent weight loss, delayed recovery of swallowing, and treatment‑related mucositis. This interventional protocol provides optimized early management including structured nutritional support and enhanced supportive care during postoperative concomitant radiochemotherapy to improve tolerance and treatment completion. Eligible adults (18–75 years) with localized head and neck squamous cell carcinoma and WHO performance status <2 are enrolled, excluding those with prior head‑and‑neck radiotherapy, contraindications to cisplatin, or recent other cancers. The trial is run at regional French centers and tracks completion of three cisplatin cycles along with functional and nutritional outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female, over 18 and under 75 years of age,
* Worl Health Organisation score \< 2,
* Treatment for a localized squamous cell carcinoma of the head and neck for which a curative treatment by concomitant post-operative radiochemotherapy based on cisplatin is retained,
* Having signed the informed consent,
* Affiliate or beneficiary of a social protection scheme.

Exclusion Criteria:

* History of other neoplastic disease less than 2 years old or progressive,
* History of radiotherapy for head and neck cancer,
* Contraindications to cisplatin,
* Pregnant or breastfeeding woman,
* Protected major (under guardianship or curatorship),
* Patient participating in a therapeutic study
* Patient unable to understand the study for any reason or to comply with the constraints of the trial

Where it's running

• CHU Amiens
  Amiens, France Recruiting
• CH Beauvais
  Beauvais, France Recruiting
• Centre Guillaume le Conquérant
  Le Havre, France Recruiting
• CHRU Lille
  Lille, France Recruiting
• Centre Henri Becquerel
  Rouen, France Recruiting
• CH Saint-Quentin
  Saint-Quentin, France Recruiting

Study contacts

• Study coordinator: Florian Clatot, MD,PhD
• Email: florian.clatot@chb.unicancer.fr
• Phone: +33232082231

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Iparomlimab plus tuvonralimab, with or without chemotherapy, for second-line and later recurrent or metastatic head and neck squamous cell carcinoma

  This will try whether combining two antibodies, iparomlimab and tuvonralimab, with or without chemotherapy helps people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed after at least one systemic treatment.

  Recruiting The Second Affiliated Hospital of Hainan Medical University · Haikou, Hainan · NCT07546383

• Cetuximab with PD-1 therapy plus chemotherapy vs PD-1 therapy with chemotherapy for recurrent/metastatic head and neck cancer

  This trial tests whether adding cetuximab to a PD-1 inhibitor plus chemotherapy helps people with recurrent or metastatic head and neck squamous cell cancer who aren’t candidates for curative treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07509099

• Neoadjuvant CADI-05 with pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma

  This will test whether adding weekly CADI-05 skin injections to pembrolizumab before surgery helps adults with resectable locally advanced head and neck squamous cell cancer.

  Recruiting at 2 sites Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania and 1 other locations · NCT07455032

• 5-Fluorouracil Response and Optimization (FROST)

  This trial will test two different dosing schedules of 5‑fluorouracil as second-line-or-later treatment for people with recurrent or metastatic head and neck squamous cell carcinoma who have already had platinum and PD‑1 inhibitor therapy.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07419464

• Amivantamab added to pembrolizumab and platinum chemotherapy versus pembrolizumab with platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial will see if adding amivantamab to pembrolizumab and platinum‑based chemotherapy helps adults with recurrent or metastatic head and neck squamous cell carcinoma who have not yet had systemic treatment in the metastatic setting.

  Recruiting at 205 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 204 other locations · NCT07276399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.